Cerecor Inc (CERC) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $15. Rodman & Renshaw advised their investors in a research report released on Apr 13, 2016.
In a different news, on Oct 20, 2015, Ronald Marcus (Chief Medical Officer) purchased 30,617 shares at $0.00 per share price.
Cerecor Inc. (Cerecor) is a United States-based biopharmaceutical company. The Company is developing treatments for patients suffering from nervous system disorders. CERC-301 is a potent and selective NR2B antagonist. Cerecor specializes in developing drugs to treat neuropsychological disorders such as anxiety and depression. Cerecor is focused on translational medicine. It is focused on the discovery development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain.